Castle Biosciences combines 36% core volume growth, a $261.7 million cash cushion, and DecisionDx-SCC reimbursement upside into an asymmetric long-term risk/reward.
Overview
Castle Biosciences is a commercial-stage precision diagnostics company whose centralized laboratories use proprietary genomic and spatial-protein algorithms to guide treatment and surveillance decisions in dermatologic oncology, gastroenterology, and immunology. Its competitive position is strongest in melanoma, where DecisionDx-Melanoma has exceeded 200,000 cumulative orders, and in emerging Barrett’s esophagus prognostics through TissueCypher. **Underlying growth remains strong despite reported revenue disruption:** Q1 2026 revenue of $83.7 million exceeded consensus of $77.46 million by 8%, while revenue excluding DecisionDx-SCC and discontinued IDgenetix grew 42% year over year. TissueCypher volumes rose 58% and melanoma volumes 16%. Management raised FY2026 revenue guidance to $345–$355 million. Valuation is conservative at approximately 1.46x trailing EV/Sales, versus higher molecular-diagnostics peer multiples, reflecting SCC reimbursement uncertainty and current operating losses. **The central catalyst is a potential late-2026 positive draft LCD for DecisionDx-SCC**, which could restore high-margin revenue at an historical $8,500 ADLT rate. Additional catalysts include AdvanceAD-Tx adoption and continued TissueCypher volume growth. The report’s five-year probability-weighted target is $78.10 versus a late-July price of $25.48.